• WuXi Biologics won two Grand Awards at the 2026 Hong Kong ESG Reporting Awards for ESG reporting and environmental impact.
• The honors covered Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact.
• Selected from 120 entries, it was the only pharmaceutical company to receive a Grand Award.
• In 2025, the Science Based Targets initiative validated its near-term, long-term and net-zero emissions reduction targets.
• The targets cover Scope 1, 2 and 3 emissions, aligned with a 1.5°C pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.